| Psoriasis vulgaris

Enstilar vs Hadlima

Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.

Deep comparison between: Enstilar vs Hadlima with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsHadlima has a higher rate of injection site reactions vs Enstilar based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Hadlima but not Enstilar, including UnitedHealthcare

Category

Enstilar

Hadlima

At A Glance

RouteTopical

FrequencyOnce daily

ClassVitamin D3 analog + corticosteroid

RouteSC injection

FrequencyEvery other week

ClassTNF-alpha blocker

Indications

Psoriasis vulgaris

Rheumatoid Arthritis
Juvenile polyarthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Psoriasis vulgaris
Hidradenitis Suppurativa
Uveitis

Dosing

Psoriasis vulgaris Apply to affected areas once daily for up to 4 weeks; maximum dose not to exceed 60 g every 4 days; rub in gently; do not use with occlusive dressings, on the face, groin, or axillae, or if skin atrophy is present at the treatment site.

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.

Juvenile polyarthritis SC every other week based on weight for patients 2 years and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg).

Crohn Disease Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction (80 or 160 mg Day 1, 40 or 80 mg Day 15), then 20 or 40 mg every other week starting Day 29.

Ulcerative Colitis 160 mg Day 1, 80 mg Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.

Psoriasis vulgaris, Uveitis 80 mg initial dose, then 40 mg every other week starting 1 week after the initial dose.

Hidradenitis Suppurativa 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

Contraindications

—

Drug Interactions

841View drug interactions

1222View drug interactions

Adverse Reactions

Postmarketing Application site burning, atrophy, striae, telangiectasia, dryness, perioral dermatitis, secondary infection, miliaria, cataracts, glaucoma, increased intraocular pressure.

Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, hyperlipidemia, flu syndrome, abdominal pain, laboratory test abnormalities.

Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.

Postmarketing Liver failure, hepatitis, autoimmune hepatitis, sarcoidosis, Merkel cell carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, systemic vasculitis, deep vein thrombosis.

Pharmacology

Enstilar Foam combines calcipotriene hydrate, a synthetic vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid; exact mechanisms of action in the treatment of plaque psoriasis are unknown.

TNF-alpha blocker; adalimumab-bwwd is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Enstilar